Added to YB: 2026-09-28
Pitch date: 2026-09-23
QURE [bullish]
uniQure N.V.
-9.88%
current return
Author Info
Care & Capital is a 23 year old value investor and Healthcare Equity Analyst in training. Sign up for the newsletter.
Company Info
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States.
Market Cap
$3.0B
Pitch Price
$42.42
Price Target
N/A
Dividend
N/A
EV/EBITDA
-15.14
P/E
-10.59
EV/Sales
145.03
Sector
Biotechnology
Category
special_situation
uniQure N.V. ($QURE) – A Small, High-Risk Bet on Huntington’s Gene Therapy
QURE: uniQure is a small starter at $44, centered on AMT-130 and whether the FDA accepts its filed Phase I/II package for accelerated approval in Huntington’s. High-dose treatment slowed progression 75% at 36 months, but the comparison rests on 12 patients and an external control. Four-year data are due this quarter; with a roughly $3.1B valuation, intracranial delivery and an FDA that has already reversed course, sizing should remain modest.
Read full article (10 min)